Procter & Gamble Health Limited (PGHL.BO) Stock Competitors & Peer Comparison
See (PGHL.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PGHL.BO | ₹6,296.25 | -0.45% | 104.1B | 31.81 | ₹197.13 | +3.28% |
| SUNPHARMA.NS | ₹1,862.90 | +2.09% | 4.4T | 38.52 | ₹47.72 | +0.90% |
| SUNPHARMA.BO | ₹1,863.45 | +2.16% | 4.4T | 40.38 | ₹45.50 | +0.90% |
| DIVISLAB.NS | ₹6,787.50 | +0.30% | 1.8T | 69.76 | ₹96.66 | +0.44% |
| DIVISLAB.BO | ₹6,784.95 | +0.26% | 1.8T | 69.73 | ₹96.67 | +0.44% |
| TORNTPHARM.NS | ₹4,457.00 | +0.26% | 1.5T | 69.36 | ₹63.87 | +0.34% |
| TORNTPHARM.BO | ₹4,457.75 | +0.34% | 1.5T | 69.99 | ₹63.25 | +0.34% |
| LUPIN.BO | ₹2,339.45 | +0.51% | 1.1T | 24.92 | ₹94.37 | +0.51% |
| ZYDUSLIFE.NS | ₹1,085.50 | +1.03% | 1.1T | 21.39 | ₹50.05 | +1.03% |
| ZYDUSLIFE.BO | ₹1,084.35 | +0.94% | 1.1T | 21.40 | ₹50.04 | +1.03% |
Stock Comparison
PGHL.BO vs SUNPHARMA.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, SUNPHARMA.NS has a market cap of 4.4T. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while SUNPHARMA.NS trades at ₹1,862.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas SUNPHARMA.NS's P/E ratio is 38.52. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, PGHL.BO is less volatile compared to SUNPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check SUNPHARMA.NS's competition here
PGHL.BO vs SUNPHARMA.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, SUNPHARMA.BO has a market cap of 4.4T. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while SUNPHARMA.BO trades at ₹1,863.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas SUNPHARMA.BO's P/E ratio is 40.38. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, PGHL.BO is less volatile compared to SUNPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check SUNPHARMA.BO's competition here
PGHL.BO vs DIVISLAB.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, DIVISLAB.NS has a market cap of 1.8T. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while DIVISLAB.NS trades at ₹6,787.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas DIVISLAB.NS's P/E ratio is 69.76. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to DIVISLAB.NS's ROE of +0.17%. Regarding short-term risk, PGHL.BO is less volatile compared to DIVISLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check DIVISLAB.NS's competition here
PGHL.BO vs DIVISLAB.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, DIVISLAB.BO has a market cap of 1.8T. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while DIVISLAB.BO trades at ₹6,784.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas DIVISLAB.BO's P/E ratio is 69.73. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to DIVISLAB.BO's ROE of +0.17%. Regarding short-term risk, PGHL.BO is less volatile compared to DIVISLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check DIVISLAB.BO's competition here
PGHL.BO vs TORNTPHARM.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, TORNTPHARM.NS has a market cap of 1.5T. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while TORNTPHARM.NS trades at ₹4,457.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas TORNTPHARM.NS's P/E ratio is 69.36. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to TORNTPHARM.NS's ROE of +0.27%. Regarding short-term risk, PGHL.BO is less volatile compared to TORNTPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check TORNTPHARM.NS's competition here
PGHL.BO vs TORNTPHARM.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, TORNTPHARM.BO has a market cap of 1.5T. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while TORNTPHARM.BO trades at ₹4,457.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas TORNTPHARM.BO's P/E ratio is 69.99. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to TORNTPHARM.BO's ROE of +0.27%. Regarding short-term risk, PGHL.BO is less volatile compared to TORNTPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check TORNTPHARM.BO's competition here
PGHL.BO vs LUPIN.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, LUPIN.BO has a market cap of 1.1T. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while LUPIN.BO trades at ₹2,339.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas LUPIN.BO's P/E ratio is 24.92. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to LUPIN.BO's ROE of +0.28%. Regarding short-term risk, PGHL.BO is less volatile compared to LUPIN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check LUPIN.BO's competition here
PGHL.BO vs ZYDUSLIFE.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, ZYDUSLIFE.NS has a market cap of 1.1T. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while ZYDUSLIFE.NS trades at ₹1,085.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas ZYDUSLIFE.NS's P/E ratio is 21.39. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to ZYDUSLIFE.NS's ROE of +0.20%. Regarding short-term risk, PGHL.BO is less volatile compared to ZYDUSLIFE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check ZYDUSLIFE.NS's competition here
PGHL.BO vs ZYDUSLIFE.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, ZYDUSLIFE.BO has a market cap of 1.1T. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while ZYDUSLIFE.BO trades at ₹1,084.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas ZYDUSLIFE.BO's P/E ratio is 21.40. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to ZYDUSLIFE.BO's ROE of +0.20%. Regarding short-term risk, PGHL.BO is less volatile compared to ZYDUSLIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check ZYDUSLIFE.BO's competition here
PGHL.BO vs LUPIN.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, LUPIN.NS has a market cap of 1.1T. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while LUPIN.NS trades at ₹2,340.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas LUPIN.NS's P/E ratio is 20.21. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to LUPIN.NS's ROE of +0.28%. Regarding short-term risk, PGHL.BO is less volatile compared to LUPIN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check LUPIN.NS's competition here
PGHL.BO vs DRREDDY.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, DRREDDY.NS has a market cap of 1.1T. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while DRREDDY.NS trades at ₹1,290.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas DRREDDY.NS's P/E ratio is 24.72. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to DRREDDY.NS's ROE of +0.12%. Regarding short-term risk, PGHL.BO is less volatile compared to DRREDDY.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check DRREDDY.NS's competition here
PGHL.BO vs DRREDDY.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, DRREDDY.BO has a market cap of 1.1T. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while DRREDDY.BO trades at ₹1,291.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas DRREDDY.BO's P/E ratio is 18.74. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to DRREDDY.BO's ROE of +0.12%. Regarding short-term risk, PGHL.BO is less volatile compared to DRREDDY.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check DRREDDY.BO's competition here
PGHL.BO vs MANKIND.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, MANKIND.BO has a market cap of 998.4B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while MANKIND.BO trades at ₹2,537.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas MANKIND.BO's P/E ratio is 52.33. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to MANKIND.BO's ROE of +0.13%. Regarding short-term risk, PGHL.BO is less volatile compared to MANKIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check MANKIND.BO's competition here
PGHL.BO vs MANKIND.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, MANKIND.NS has a market cap of 997.1B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while MANKIND.NS trades at ₹2,538.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas MANKIND.NS's P/E ratio is 52.28. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, PGHL.BO is less volatile compared to MANKIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check MANKIND.NS's competition here
PGHL.BO vs AUROPHARMA.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, AUROPHARMA.BO has a market cap of 862B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while AUROPHARMA.BO trades at ₹1,492.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas AUROPHARMA.BO's P/E ratio is 25.43. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to AUROPHARMA.BO's ROE of +0.10%. Regarding short-term risk, PGHL.BO is less volatile compared to AUROPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check AUROPHARMA.BO's competition here
PGHL.BO vs AUROPHARMA.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, AUROPHARMA.NS has a market cap of 861.8B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while AUROPHARMA.NS trades at ₹1,491.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas AUROPHARMA.NS's P/E ratio is 24.82. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to AUROPHARMA.NS's ROE of +0.10%. Regarding short-term risk, PGHL.BO is less volatile compared to AUROPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check AUROPHARMA.NS's competition here
PGHL.BO vs LAURUSLABS.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, LAURUSLABS.NS has a market cap of 762.8B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while LAURUSLABS.NS trades at ₹1,435.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas LAURUSLABS.NS's P/E ratio is 85.53. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to LAURUSLABS.NS's ROE of +0.19%. Regarding short-term risk, PGHL.BO is less volatile compared to LAURUSLABS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check LAURUSLABS.NS's competition here
PGHL.BO vs LAURUSLABS.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, LAURUSLABS.BO has a market cap of 762.1B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while LAURUSLABS.BO trades at ₹1,436.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas LAURUSLABS.BO's P/E ratio is 85.57. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to LAURUSLABS.BO's ROE of +0.19%. Regarding short-term risk, PGHL.BO is less volatile compared to LAURUSLABS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check LAURUSLABS.BO's competition here
PGHL.BO vs ALKEM.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, ALKEM.NS has a market cap of 642.5B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while ALKEM.NS trades at ₹5,367.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas ALKEM.NS's P/E ratio is 27.91. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to ALKEM.NS's ROE of +0.18%. Regarding short-term risk, PGHL.BO is less volatile compared to ALKEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check ALKEM.NS's competition here
PGHL.BO vs ALKEM.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, ALKEM.BO has a market cap of 641.9B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while ALKEM.BO trades at ₹5,366.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas ALKEM.BO's P/E ratio is 27.91. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to ALKEM.BO's ROE of +0.18%. Regarding short-term risk, PGHL.BO is less volatile compared to ALKEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check ALKEM.BO's competition here
PGHL.BO vs GLENMARK.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, GLENMARK.BO has a market cap of 624.7B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while GLENMARK.BO trades at ₹2,189.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas GLENMARK.BO's P/E ratio is 45.83. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to GLENMARK.BO's ROE of +0.14%. Regarding short-term risk, PGHL.BO is less volatile compared to GLENMARK.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check GLENMARK.BO's competition here
PGHL.BO vs GLENMARK.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, GLENMARK.NS has a market cap of 624.7B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while GLENMARK.NS trades at ₹2,191.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas GLENMARK.NS's P/E ratio is 45.82. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to GLENMARK.NS's ROE of +0.14%. Regarding short-term risk, PGHL.BO is less volatile compared to GLENMARK.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check GLENMARK.NS's competition here
PGHL.BO vs SUVENPHAR.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while SUVENPHAR.NS trades at ₹1,078.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to SUVENPHAR.NS's ROE of +0.09%. Regarding short-term risk, PGHL.BO is less volatile compared to SUVENPHAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check SUVENPHAR.NS's competition here
PGHL.BO vs SUVENPHAR.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while SUVENPHAR.BO trades at ₹1,075.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to SUVENPHAR.BO's ROE of +0.07%. Regarding short-term risk, PGHL.BO is less volatile compared to SUVENPHAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check SUVENPHAR.BO's competition here
PGHL.BO vs IPCALAB.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, IPCALAB.NS has a market cap of 402.3B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while IPCALAB.NS trades at ₹1,597.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas IPCALAB.NS's P/E ratio is 35.27. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to IPCALAB.NS's ROE of +0.15%. Regarding short-term risk, PGHL.BO is less volatile compared to IPCALAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check IPCALAB.NS's competition here
PGHL.BO vs IPCALAB.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, IPCALAB.BO has a market cap of 402.1B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while IPCALAB.BO trades at ₹1,598.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas IPCALAB.BO's P/E ratio is 35.23. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to IPCALAB.BO's ROE of +0.15%. Regarding short-term risk, PGHL.BO is less volatile compared to IPCALAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check IPCALAB.BO's competition here
PGHL.BO vs AJANTPHARM.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, AJANTPHARM.NS has a market cap of 383B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while AJANTPHARM.NS trades at ₹3,189.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas AJANTPHARM.NS's P/E ratio is 36.33. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to AJANTPHARM.NS's ROE of +0.26%. Regarding short-term risk, PGHL.BO is less volatile compared to AJANTPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check AJANTPHARM.NS's competition here
PGHL.BO vs AJANTPHARM.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, AJANTPHARM.BO has a market cap of 382.5B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while AJANTPHARM.BO trades at ₹3,188.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas AJANTPHARM.BO's P/E ratio is 37.76. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to AJANTPHARM.BO's ROE of +0.26%. Regarding short-term risk, PGHL.BO is less volatile compared to AJANTPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check AJANTPHARM.BO's competition here
PGHL.BO vs JBCHEPHARM.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, JBCHEPHARM.NS has a market cap of 352.2B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while JBCHEPHARM.NS trades at ₹2,206.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas JBCHEPHARM.NS's P/E ratio is 49.28. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to JBCHEPHARM.NS's ROE of +0.19%. Regarding short-term risk, PGHL.BO is less volatile compared to JBCHEPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check JBCHEPHARM.NS's competition here
PGHL.BO vs JBCHEPHARM.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, JBCHEPHARM.BO has a market cap of 351.5B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while JBCHEPHARM.BO trades at ₹2,208.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas JBCHEPHARM.BO's P/E ratio is 49.19. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to JBCHEPHARM.BO's ROE of +0.19%. Regarding short-term risk, PGHL.BO is less volatile compared to JBCHEPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check JBCHEPHARM.BO's competition here
PGHL.BO vs EMCURE.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, EMCURE.NS has a market cap of 338B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while EMCURE.NS trades at ₹1,791.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas EMCURE.NS's P/E ratio is 36.55. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to EMCURE.NS's ROE of +0.20%. Regarding short-term risk, PGHL.BO is less volatile compared to EMCURE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check EMCURE.NS's competition here
PGHL.BO vs WOCKPHARMA.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, WOCKPHARMA.NS has a market cap of 326.8B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while WOCKPHARMA.NS trades at ₹2,013.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas WOCKPHARMA.NS's P/E ratio is 154.11. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to WOCKPHARMA.NS's ROE of +0.05%. Regarding short-term risk, PGHL.BO is less volatile compared to WOCKPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check WOCKPHARMA.NS's competition here
PGHL.BO vs WOCKPHARMA.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, WOCKPHARMA.BO has a market cap of 326.8B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while WOCKPHARMA.BO trades at ₹2,013.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas WOCKPHARMA.BO's P/E ratio is 153.86. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to WOCKPHARMA.BO's ROE of +0.05%. Regarding short-term risk, PGHL.BO is less volatile compared to WOCKPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check WOCKPHARMA.BO's competition here
PGHL.BO vs PEL.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while PEL.NS trades at ₹1,124.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to PEL.NS's ROE of +0.02%. Regarding short-term risk, PGHL.BO is less volatile compared to PEL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check PEL.NS's competition here
PGHL.BO vs NEULANDLAB.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, NEULANDLAB.BO has a market cap of 222.7B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while NEULANDLAB.BO trades at ₹17,201.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas NEULANDLAB.BO's P/E ratio is 61.06. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to NEULANDLAB.BO's ROE of +0.22%. Regarding short-term risk, PGHL.BO is less volatile compared to NEULANDLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check NEULANDLAB.BO's competition here
PGHL.BO vs NEULANDLAB.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, NEULANDLAB.NS has a market cap of 222.5B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while NEULANDLAB.NS trades at ₹17,224.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas NEULANDLAB.NS's P/E ratio is 61.02. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to NEULANDLAB.NS's ROE of +0.22%. Regarding short-term risk, PGHL.BO is less volatile compared to NEULANDLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check NEULANDLAB.NS's competition here
PGHL.BO vs ASTRAZEN.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, ASTRAZEN.NS has a market cap of 210.8B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while ASTRAZEN.NS trades at ₹8,569.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas ASTRAZEN.NS's P/E ratio is 112.70. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to ASTRAZEN.NS's ROE of +0.23%. Regarding short-term risk, PGHL.BO is less volatile compared to ASTRAZEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check ASTRAZEN.NS's competition here
PGHL.BO vs PPLPHARMA.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, PPLPHARMA.NS has a market cap of 210.8B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while PPLPHARMA.NS trades at ₹158.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas PPLPHARMA.NS's P/E ratio is -64.59. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to PPLPHARMA.NS's ROE of -0.04%. Regarding short-term risk, PGHL.BO is less volatile compared to PPLPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check PPLPHARMA.NS's competition here
PGHL.BO vs PPLPHARMA.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, PPLPHARMA.BO has a market cap of 210.8B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while PPLPHARMA.BO trades at ₹158.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas PPLPHARMA.BO's P/E ratio is -64.55. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to PPLPHARMA.BO's ROE of -0.04%. Regarding short-term risk, PGHL.BO is less volatile compared to PPLPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check PPLPHARMA.BO's competition here
PGHL.BO vs ASTRAZEN.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, ASTRAZEN.BO has a market cap of 210B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while ASTRAZEN.BO trades at ₹8,545.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas ASTRAZEN.BO's P/E ratio is 112.39. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to ASTRAZEN.BO's ROE of +0.23%. Regarding short-term risk, PGHL.BO is less volatile compared to ASTRAZEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check ASTRAZEN.BO's competition here
PGHL.BO vs ERIS.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, ERIS.NS has a market cap of 200.7B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while ERIS.NS trades at ₹1,436.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas ERIS.NS's P/E ratio is 31.98. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to ERIS.NS's ROE of +0.19%. Regarding short-term risk, PGHL.BO is less volatile compared to ERIS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check ERIS.NS's competition here
PGHL.BO vs ERIS.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, ERIS.BO has a market cap of 200.4B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while ERIS.BO trades at ₹1,433.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas ERIS.BO's P/E ratio is 31.92. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to ERIS.BO's ROE of +0.19%. Regarding short-term risk, PGHL.BO is less volatile compared to ERIS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check ERIS.BO's competition here
PGHL.BO vs GRANULES.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, GRANULES.NS has a market cap of 195B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while GRANULES.NS trades at ₹778.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas GRANULES.NS's P/E ratio is 32.16. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to GRANULES.NS's ROE of +0.14%. Regarding short-term risk, PGHL.BO is less volatile compared to GRANULES.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check GRANULES.NS's competition here
PGHL.BO vs GRANULES.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, GRANULES.BO has a market cap of 194.7B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while GRANULES.BO trades at ₹778.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas GRANULES.BO's P/E ratio is 34.94. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to GRANULES.BO's ROE of +0.14%. Regarding short-term risk, PGHL.BO is less volatile compared to GRANULES.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check GRANULES.BO's competition here
PGHL.BO vs CAPLIPOINT.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, CAPLIPOINT.BO has a market cap of 190.5B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while CAPLIPOINT.BO trades at ₹2,534.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas CAPLIPOINT.BO's P/E ratio is 29.77. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to CAPLIPOINT.BO's ROE of +0.21%. Regarding short-term risk, PGHL.BO is less volatile compared to CAPLIPOINT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check CAPLIPOINT.BO's competition here
PGHL.BO vs CAPLIPOINT.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, CAPLIPOINT.NS has a market cap of 190.3B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while CAPLIPOINT.NS trades at ₹2,537.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas CAPLIPOINT.NS's P/E ratio is 29.74. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to CAPLIPOINT.NS's ROE of +0.21%. Regarding short-term risk, PGHL.BO is less volatile compared to CAPLIPOINT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check CAPLIPOINT.NS's competition here
PGHL.BO vs NATCOPHARM.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, NATCOPHARM.BO has a market cap of 159.2B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while NATCOPHARM.BO trades at ₹884.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas NATCOPHARM.BO's P/E ratio is 10.34. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to NATCOPHARM.BO's ROE of +0.17%. Regarding short-term risk, PGHL.BO is less volatile compared to NATCOPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check NATCOPHARM.BO's competition here
PGHL.BO vs NATCOPHARM.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, NATCOPHARM.NS has a market cap of 159.2B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while NATCOPHARM.NS trades at ₹884.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas NATCOPHARM.NS's P/E ratio is 11.23. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to NATCOPHARM.NS's ROE of +0.17%. Regarding short-term risk, PGHL.BO is less volatile compared to NATCOPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check NATCOPHARM.NS's competition here
PGHL.BO vs COHANCE.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, COHANCE.BO has a market cap of 156.2B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while COHANCE.BO trades at ₹406.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas COHANCE.BO's P/E ratio is 86.88. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to COHANCE.BO's ROE of +0.06%. Regarding short-term risk, PGHL.BO is less volatile compared to COHANCE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check COHANCE.BO's competition here
PGHL.BO vs COHANCE.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, COHANCE.NS has a market cap of 155.3B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while COHANCE.NS trades at ₹405.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas COHANCE.NS's P/E ratio is 86.91. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to COHANCE.NS's ROE of +0.06%. Regarding short-term risk, PGHL.BO is less volatile compared to COHANCE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check COHANCE.NS's competition here
PGHL.BO vs JUBLPHARMA.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, JUBLPHARMA.NS has a market cap of 154.2B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while JUBLPHARMA.NS trades at ₹956.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas JUBLPHARMA.NS's P/E ratio is 38.81. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to JUBLPHARMA.NS's ROE of +0.06%. Regarding short-term risk, PGHL.BO is less volatile compared to JUBLPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check JUBLPHARMA.NS's competition here
PGHL.BO vs JUBLPHARMA.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, JUBLPHARMA.BO has a market cap of 154.1B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while JUBLPHARMA.BO trades at ₹957.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas JUBLPHARMA.BO's P/E ratio is 38.83. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to JUBLPHARMA.BO's ROE of +0.06%. Regarding short-term risk, PGHL.BO is less volatile compared to JUBLPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check JUBLPHARMA.BO's competition here
PGHL.BO vs APLLTD.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, APLLTD.NS has a market cap of 150B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while APLLTD.NS trades at ₹780.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas APLLTD.NS's P/E ratio is 22.24. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to APLLTD.NS's ROE of +0.13%. Regarding short-term risk, PGHL.BO is less volatile compared to APLLTD.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check APLLTD.NS's competition here
PGHL.BO vs APLLTD.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, APLLTD.BO has a market cap of 149.8B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while APLLTD.BO trades at ₹780.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas APLLTD.BO's P/E ratio is 22.17. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to APLLTD.BO's ROE of +0.13%. Regarding short-term risk, PGHL.BO is less volatile compared to APLLTD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check APLLTD.BO's competition here
PGHL.BO vs GLS.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while GLS.NS trades at ₹1,086.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to GLS.NS's ROE of +0.21%. Regarding short-term risk, PGHL.BO is less volatile compared to GLS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check GLS.NS's competition here
PGHL.BO vs GLS.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while GLS.BO trades at ₹1,085.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to GLS.BO's ROE of +0.09%. Regarding short-term risk, PGHL.BO is less volatile compared to GLS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check GLS.BO's competition here
PGHL.BO vs ALIVUS.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, ALIVUS.NS has a market cap of 131.4B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while ALIVUS.NS trades at ₹1,081.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas ALIVUS.NS's P/E ratio is 23.33. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to ALIVUS.NS's ROE of +0.18%. Regarding short-term risk, PGHL.BO is less volatile compared to ALIVUS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check ALIVUS.NS's competition here
PGHL.BO vs ALIVUS.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, ALIVUS.BO has a market cap of 131.2B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while ALIVUS.BO trades at ₹1,082.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas ALIVUS.BO's P/E ratio is 23.31. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to ALIVUS.BO's ROE of +0.21%. Regarding short-term risk, PGHL.BO is less volatile compared to ALIVUS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check ALIVUS.BO's competition here
PGHL.BO vs VIYASH.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, VIYASH.NS has a market cap of 111.3B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while VIYASH.NS trades at ₹271.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas VIYASH.NS's P/E ratio is 63.58. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to VIYASH.NS's ROE of +0.09%. Regarding short-term risk, PGHL.BO is less volatile compared to VIYASH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check VIYASH.NS's competition here
PGHL.BO vs CAPPL.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while CAPPL.BO trades at ₹1,446.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, PGHL.BO is less volatile compared to CAPPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check CAPPL.BO's competition here
PGHL.BO vs SHILPAMED.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, SHILPAMED.NS has a market cap of 107.8B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while SHILPAMED.NS trades at ₹547.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas SHILPAMED.NS's P/E ratio is 44.36. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to SHILPAMED.NS's ROE of +0.10%. Regarding short-term risk, PGHL.BO is less volatile compared to SHILPAMED.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check SHILPAMED.NS's competition here
PGHL.BO vs PGHL.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, PGHL.NS has a market cap of 103.6B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while PGHL.NS trades at ₹6,305.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas PGHL.NS's P/E ratio is 31.73. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to PGHL.NS's ROE of +0.59%. Regarding short-term risk, PGHL.BO is less volatile compared to PGHL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check PGHL.NS's competition here
PGHL.BO vs STAR.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, STAR.NS has a market cap of 102.4B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while STAR.NS trades at ₹1,116.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas STAR.NS's P/E ratio is 18.42. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to STAR.NS's ROE of +0.20%. Regarding short-term risk, PGHL.BO is less volatile compared to STAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check STAR.NS's competition here
PGHL.BO vs STAR.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, STAR.BO has a market cap of 102.1B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while STAR.BO trades at ₹1,116.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas STAR.BO's P/E ratio is 18.38. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to STAR.BO's ROE of +0.20%. Regarding short-term risk, PGHL.BO is less volatile compared to STAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check STAR.BO's competition here
PGHL.BO vs SUDEEPPHRM.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, SUDEEPPHRM.NS has a market cap of 95.2B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while SUDEEPPHRM.NS trades at ₹831.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas SUDEEPPHRM.NS's P/E ratio is 56.69. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to SUDEEPPHRM.NS's ROE of N/A. Regarding short-term risk, PGHL.BO is less volatile compared to SUDEEPPHRM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check SUDEEPPHRM.NS's competition here
PGHL.BO vs AKUMS.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, AKUMS.NS has a market cap of 92.6B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while AKUMS.NS trades at ₹617.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas AKUMS.NS's P/E ratio is 36.32. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to AKUMS.NS's ROE of +0.08%. Regarding short-term risk, PGHL.BO is less volatile compared to AKUMS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check AKUMS.NS's competition here
PGHL.BO vs SPARC.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, SPARC.BO has a market cap of 77.3B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while SPARC.BO trades at ₹237.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas SPARC.BO's P/E ratio is 4.97. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to SPARC.BO's ROE of +11.09%. Regarding short-term risk, PGHL.BO is less volatile compared to SPARC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check SPARC.BO's competition here
PGHL.BO vs SPARC.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, SPARC.NS has a market cap of 77.3B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while SPARC.NS trades at ₹238.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas SPARC.NS's P/E ratio is 4.98. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to SPARC.NS's ROE of +11.09%. Regarding short-term risk, PGHL.BO is less volatile compared to SPARC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check SPARC.NS's competition here
PGHL.BO vs FDC.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, FDC.NS has a market cap of 63.4B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while FDC.NS trades at ₹403.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas FDC.NS's P/E ratio is 22.52. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to FDC.NS's ROE of +0.12%. Regarding short-term risk, PGHL.BO is less volatile compared to FDC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check FDC.NS's competition here
PGHL.BO vs FDC.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, FDC.BO has a market cap of 63.4B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while FDC.BO trades at ₹403.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas FDC.BO's P/E ratio is 22.49. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to FDC.BO's ROE of +0.12%. Regarding short-term risk, PGHL.BO is less volatile compared to FDC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check FDC.BO's competition here
PGHL.BO vs AARTIPHARM.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, AARTIPHARM.NS has a market cap of 62.7B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while AARTIPHARM.NS trades at ₹678.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas AARTIPHARM.NS's P/E ratio is 35.96. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to AARTIPHARM.NS's ROE of +0.09%. Regarding short-term risk, PGHL.BO is less volatile compared to AARTIPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check AARTIPHARM.NS's competition here
PGHL.BO vs AARTIPHARM.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, AARTIPHARM.BO has a market cap of 62.7B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while AARTIPHARM.BO trades at ₹677.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas AARTIPHARM.BO's P/E ratio is 35.94. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to AARTIPHARM.BO's ROE of +0.09%. Regarding short-term risk, PGHL.BO is less volatile compared to AARTIPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check AARTIPHARM.BO's competition here
PGHL.BO vs SUVEN.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, SUVEN.BO has a market cap of 60.2B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while SUVEN.BO trades at ₹265.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas SUVEN.BO's P/E ratio is -21.78. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to SUVEN.BO's ROE of -1.01%. Regarding short-term risk, PGHL.BO is less volatile compared to SUVEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check SUVEN.BO's competition here
PGHL.BO vs SUVEN.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, SUVEN.NS has a market cap of 60.1B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while SUVEN.NS trades at ₹265.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas SUVEN.NS's P/E ratio is -22.09. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to SUVEN.NS's ROE of -1.01%. Regarding short-term risk, PGHL.BO is less volatile compared to SUVEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check SUVEN.NS's competition here
PGHL.BO vs INNOVACAP.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, INNOVACAP.NS has a market cap of 54.3B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while INNOVACAP.NS trades at ₹935.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas INNOVACAP.NS's P/E ratio is 38.62. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to INNOVACAP.NS's ROE of +0.14%. Regarding short-term risk, PGHL.BO is less volatile compared to INNOVACAP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check INNOVACAP.NS's competition here
PGHL.BO vs SHILPAMED.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, SHILPAMED.BO has a market cap of 53.9B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while SHILPAMED.BO trades at ₹545.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas SHILPAMED.BO's P/E ratio is 44.38. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to SHILPAMED.BO's ROE of +0.10%. Regarding short-term risk, PGHL.BO is less volatile compared to SHILPAMED.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check SHILPAMED.BO's competition here
PGHL.BO vs BLISSGVS.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, BLISSGVS.BO has a market cap of 51.5B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while BLISSGVS.BO trades at ₹473.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas BLISSGVS.BO's P/E ratio is 40.52. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to BLISSGVS.BO's ROE of +0.12%. Regarding short-term risk, PGHL.BO is less volatile compared to BLISSGVS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check BLISSGVS.BO's competition here
PGHL.BO vs BLISSGVS.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, BLISSGVS.NS has a market cap of 51.4B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while BLISSGVS.NS trades at ₹473.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas BLISSGVS.NS's P/E ratio is 40.46. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to BLISSGVS.NS's ROE of +0.12%. Regarding short-term risk, PGHL.BO is less volatile compared to BLISSGVS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check BLISSGVS.NS's competition here
PGHL.BO vs SEQUENT.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while SEQUENT.NS trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to SEQUENT.NS's ROE of +0.06%. Regarding short-term risk, PGHL.BO is less volatile compared to SEQUENT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check SEQUENT.NS's competition here
PGHL.BO vs SEQUENT.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while SEQUENT.BO trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to SEQUENT.BO's ROE of +0.06%. Regarding short-term risk, PGHL.BO is less volatile compared to SEQUENT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check SEQUENT.BO's competition here
PGHL.BO vs ORCHPHARMA.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, ORCHPHARMA.NS has a market cap of 49.7B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while ORCHPHARMA.NS trades at ₹958.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas ORCHPHARMA.NS's P/E ratio is 239.38. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to ORCHPHARMA.NS's ROE of +0.02%. Regarding short-term risk, PGHL.BO is less volatile compared to ORCHPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check ORCHPHARMA.NS's competition here
PGHL.BO vs ORCHPHARMA.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, ORCHPHARMA.BO has a market cap of 49.7B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while ORCHPHARMA.BO trades at ₹958.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas ORCHPHARMA.BO's P/E ratio is 241.25. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to ORCHPHARMA.BO's ROE of +0.02%. Regarding short-term risk, PGHL.BO is less volatile compared to ORCHPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check ORCHPHARMA.BO's competition here
PGHL.BO vs GUJTHEM.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, GUJTHEM.NS has a market cap of 41.8B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while GUJTHEM.NS trades at ₹402.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas GUJTHEM.NS's P/E ratio is 89.61. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to GUJTHEM.NS's ROE of +0.17%. Regarding short-term risk, PGHL.BO is less volatile compared to GUJTHEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check GUJTHEM.NS's competition here
PGHL.BO vs IOLCP.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, IOLCP.BO has a market cap of 38.3B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while IOLCP.BO trades at ₹130.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas IOLCP.BO's P/E ratio is 27.77. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to IOLCP.BO's ROE of +0.08%. Regarding short-term risk, PGHL.BO is less volatile compared to IOLCP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check IOLCP.BO's competition here
PGHL.BO vs IOLCP.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, IOLCP.NS has a market cap of 38.2B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while IOLCP.NS trades at ₹130.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas IOLCP.NS's P/E ratio is 27.76. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to IOLCP.NS's ROE of +0.08%. Regarding short-term risk, PGHL.BO is less volatile compared to IOLCP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check IOLCP.NS's competition here
PGHL.BO vs RPGLIFE.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, RPGLIFE.BO has a market cap of 37.8B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while RPGLIFE.BO trades at ₹2,333.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas RPGLIFE.BO's P/E ratio is 32.69. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to RPGLIFE.BO's ROE of +0.21%. Regarding short-term risk, PGHL.BO is less volatile compared to RPGLIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check RPGLIFE.BO's competition here
PGHL.BO vs RPGLIFE.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, RPGLIFE.NS has a market cap of 37.7B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while RPGLIFE.NS trades at ₹2,334.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas RPGLIFE.NS's P/E ratio is 32.73. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to RPGLIFE.NS's ROE of +0.21%. Regarding short-term risk, PGHL.BO is less volatile compared to RPGLIFE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check RPGLIFE.NS's competition here
PGHL.BO vs GUFICBIO.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, GUFICBIO.NS has a market cap of 35.6B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while GUFICBIO.NS trades at ₹360.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas GUFICBIO.NS's P/E ratio is 55.51. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to GUFICBIO.NS's ROE of +0.10%. Regarding short-term risk, PGHL.BO is less volatile compared to GUFICBIO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check GUFICBIO.NS's competition here
PGHL.BO vs GUFICBIO.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, GUFICBIO.BO has a market cap of 35.6B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while GUFICBIO.BO trades at ₹361.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas GUFICBIO.BO's P/E ratio is 55.63. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to GUFICBIO.BO's ROE of +0.10%. Regarding short-term risk, PGHL.BO is less volatile compared to GUFICBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check GUFICBIO.BO's competition here
PGHL.BO vs NOVARTIND.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, NOVARTIND.NS has a market cap of 34.3B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while NOVARTIND.NS trades at ₹1,491.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas NOVARTIND.NS's P/E ratio is 36.82. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to NOVARTIND.NS's ROE of +0.12%. Regarding short-term risk, PGHL.BO is less volatile compared to NOVARTIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check NOVARTIND.NS's competition here
PGHL.BO vs NOVARTIND.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, NOVARTIND.BO has a market cap of 34.3B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while NOVARTIND.BO trades at ₹1,490.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas NOVARTIND.BO's P/E ratio is 36.74. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to NOVARTIND.BO's ROE of +0.12%. Regarding short-term risk, PGHL.BO is less volatile compared to NOVARTIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check NOVARTIND.BO's competition here
PGHL.BO vs AARTIDRUGS.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, AARTIDRUGS.BO has a market cap of 33.8B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while AARTIDRUGS.BO trades at ₹376.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas AARTIDRUGS.BO's P/E ratio is 17.37. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to AARTIDRUGS.BO's ROE of +0.14%. Regarding short-term risk, PGHL.BO is less volatile compared to AARTIDRUGS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check AARTIDRUGS.BO's competition here
PGHL.BO vs AARTIDRUGS.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, AARTIDRUGS.NS has a market cap of 33.8B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while AARTIDRUGS.NS trades at ₹376.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas AARTIDRUGS.NS's P/E ratio is 17.35. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to AARTIDRUGS.NS's ROE of +0.14%. Regarding short-term risk, PGHL.BO is less volatile compared to AARTIDRUGS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check AARTIDRUGS.NS's competition here
PGHL.BO vs UNICHEMLAB.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, UNICHEMLAB.BO has a market cap of 31.3B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while UNICHEMLAB.BO trades at ₹448.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas UNICHEMLAB.BO's P/E ratio is 12.43. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to UNICHEMLAB.BO's ROE of +0.10%. Regarding short-term risk, PGHL.BO is less volatile compared to UNICHEMLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check UNICHEMLAB.BO's competition here
PGHL.BO vs UNICHEMLAB.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, UNICHEMLAB.NS has a market cap of 31.3B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while UNICHEMLAB.NS trades at ₹447.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas UNICHEMLAB.NS's P/E ratio is 12.40. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to UNICHEMLAB.NS's ROE of +0.10%. Regarding short-term risk, PGHL.BO is less volatile compared to UNICHEMLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check UNICHEMLAB.NS's competition here
PGHL.BO vs MOREPENLAB.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, MOREPENLAB.BO has a market cap of 27.1B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while MOREPENLAB.BO trades at ₹50.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas MOREPENLAB.BO's P/E ratio is 27.69. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to MOREPENLAB.BO's ROE of +0.08%. Regarding short-term risk, PGHL.BO is less volatile compared to MOREPENLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check MOREPENLAB.BO's competition here
PGHL.BO vs SOLARA.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, SOLARA.NS has a market cap of 27.1B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while SOLARA.NS trades at ₹586.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas SOLARA.NS's P/E ratio is -329.30. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to SOLARA.NS's ROE of -0.01%. Regarding short-term risk, PGHL.BO is less volatile compared to SOLARA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check SOLARA.NS's competition here
PGHL.BO vs MOREPENLAB.NS Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, MOREPENLAB.NS has a market cap of 27.1B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while MOREPENLAB.NS trades at ₹50.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas MOREPENLAB.NS's P/E ratio is 28.61. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to MOREPENLAB.NS's ROE of +0.08%. Regarding short-term risk, PGHL.BO is less volatile compared to MOREPENLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check MOREPENLAB.NS's competition here
PGHL.BO vs SOLARA.BO Comparison June 2026
PGHL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.BO stands at 104.1B. In comparison, SOLARA.BO has a market cap of 27.1B. Regarding current trading prices, PGHL.BO is priced at ₹6,296.25, while SOLARA.BO trades at ₹586.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.BO currently has a P/E ratio of 31.81, whereas SOLARA.BO's P/E ratio is -339.16. In terms of profitability, PGHL.BO's ROE is +0.59%, compared to SOLARA.BO's ROE of -0.01%. Regarding short-term risk, PGHL.BO is less volatile compared to SOLARA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PGHL.BO.Check SOLARA.BO's competition here